Anillin antibody | knockout validation | Abcam ab211872

This is a knockout-validated antibody summary, based on the publication "Alternatively spliced ANLN isoforms synergistically contribute to the progression of head and neck squamous cell carcinoma", as cited below [1]. Labome curates formal publications to compile a list of antibodies with unambiguous specificity within Validated Antibody Database (VAD).

Anillin antibody | knockout validation | Abcam ab211872 figure 1
Figure 1. ANLN was knocked out in SCC-9 cells using CRISPR/Cas9. From [1].
Antibody information

Mouse monoclonal IgG1

Company: Abcam

Antibody: Anillin

Catalog number: ab211872

Summary: Mouse monoclonal antibody against a recombinant fragment corresponding to human Anillin (aa 300-500). Reacts with human by western blot, immunocytochemistry/immunofluorescence and immunohistochemistry (paraffin).

Validation Method

Western blot

Sample

Control and ANLN-KO SCC-9 cells.

Primary incubation

1:1,000 dilution at 4°C overnight.

Detection

Chemiluminescence (ECL, Forevergen, Guangzhou, China).

Clone note

The same clone (CL0303) is sold as Novus Biologicals NBP2-52908; MilliporeSigma AMAB90662; Abnova MAB15596; Abcam ab211872; Invitrogen MA5-31342; Atlas Antibodies AMAb90662.

References
  1. Guo E, Mao X, Wang X, Guo L, An C, Zhang C, et al. Alternatively spliced ANLN isoforms synergistically contribute to the progression of head and neck squamous cell carcinoma. Cell Death Dis. 2021;12:764 pubmed publisher